These 5 Healthcare Penny Stocks Are Poised To Jump

2. Discovery Laboratories, Inc. (NASDAQ:DSCO)

Investors with Long Positions (as of June 30): 8

Aggregate Value of Investors’ Holdings (as of June 30): $15.17 Million

Many professional money managers walked out of the company during the April-June quarter, which is not surprising given that Discovery Laboratories, Inc. (NASDAQ:DSCO)’s stock cratered by more than 44% during this period. The total number of hedgies with investments in the company dropped by three and the aggregate amount of shares they held was cut in half, falling by $15.31 million. At the end of June the aggregate investment still accounted for a hefty 26% of the company’s common shares. Discovery Laboratories’ stock is down by over 67% year-to-date. The $42.29 million specialty biotechnology company delivered a net loss per share of $0.13 in its financial results for the second quarter, which was in line with the estimates. Quarterly revenues of $0.08 million were however $0.19 million short of expectations. The company’s lead program AEROSURF aims to deliver aerosolized surfactant to premature infants suffering from respiratory distress syndrome. Kevin Kotler‘s healthcare-focused Broadfin Capital is the largest shareholder of Discovery Laboratories, Inc. (NASDAQ:DSCO) within our database, holding more than 7.82 million shares valued at $5.32 million.